ES527963A0 - Un procedimiento de inmunoensayo - Google Patents

Un procedimiento de inmunoensayo

Info

Publication number
ES527963A0
ES527963A0 ES527963A ES527963A ES527963A0 ES 527963 A0 ES527963 A0 ES 527963A0 ES 527963 A ES527963 A ES 527963A ES 527963 A ES527963 A ES 527963A ES 527963 A0 ES527963 A0 ES 527963A0
Authority
ES
Spain
Prior art keywords
assay procedure
immuno assay
immuno
procedure
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES527963A
Other languages
English (en)
Other versions
ES8503441A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES527963A0 publication Critical patent/ES527963A0/es
Publication of ES8503441A1 publication Critical patent/ES8503441A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES527963A 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo Expired ES8503441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES527963A0 true ES527963A0 (es) 1985-02-16
ES8503441A1 ES8503441A1 (es) 1985-02-16

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533931A Granted ES533931A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533930A Granted ES533930A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.

Family Applications After (5)

Application Number Title Priority Date Filing Date
ES533931A Granted ES533931A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533930A Granted ES533930A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES521370A0 (es)
FI (2) FI900212A7 (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1214123A (en) * 1983-01-20 1986-11-18 Masashi Matsui Cell lines for use in the preparation of hybridoma cells
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3583278D1 (de) * 1984-04-23 1991-07-25 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
EP0241907A3 (en) 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
DE69130561T2 (de) * 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
KR101274524B1 (ko) 2004-03-16 2013-06-19 온코노바 테라퓨틱스, 인코포레이티드 증식성 질병 치료용 치환 페녹시- 및 페닐티오- 유도체
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
RU2474585C2 (ru) 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US10227407B2 (en) 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
IL287938B2 (en) 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
TW202317190A (zh) 2021-06-29 2023-05-01 美商思進公司 以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
GB8530308D0 (en) 1986-01-22
GB2167086A (en) 1986-05-21
FI834529A0 (fi) 1983-12-09
JPH0753600A (ja) 1995-02-28
ES8606655A1 (es) 1986-04-01
JPS6312276A (ja) 1988-01-19
EP0105360A1 (en) 1984-04-18
FI900212A0 (fi) 1990-01-15
ES8607386A1 (es) 1986-05-16
ES538727A0 (es) 1986-02-01
GB2167086B (en) 1987-03-04
FI900212A7 (fi) 1990-01-15
ES8603080A1 (es) 1985-12-01
GB2128631B (en) 1987-02-25
CH672796A5 (es) 1989-12-29
ES8506091A1 (es) 1985-06-16
ES8503441A1 (es) 1985-02-16
GB8332646D0 (en) 1984-01-11
ES533931A0 (es) 1985-06-16
GB2168998B (en) 1987-03-04
GB8530310D0 (en) 1986-01-22
GB2128631A (en) 1984-05-02
FI834529L (fi) 1983-12-09
GB8530309D0 (en) 1986-01-22
ES545247A0 (es) 1986-05-16
GB2169921A (en) 1986-07-23
IT1219778B (it) 1990-05-24
ES537257A0 (es) 1986-04-01
ES8604424A1 (es) 1986-02-01
JPH0753119B2 (ja) 1995-06-07
JP2562002B2 (ja) 1996-12-11
ES533930A0 (es) 1985-12-01
AU550486B2 (en) 1986-03-20
EP0105360A4 (en) 1986-07-08
ES8504461A1 (es) 1985-04-16
IT8320548A0 (it) 1983-04-12
AT394577B (de) 1992-05-11
WO1983003679A1 (en) 1983-10-27
FI834529A7 (fi) 1983-12-09
AU1555983A (en) 1983-11-04
GB2168998A (en) 1986-07-02
GB2169921B (en) 1987-03-04
CA1213229A (en) 1986-10-28
ATA901883A (de) 1991-10-15
ES521370A0 (es) 1985-04-16

Similar Documents

Publication Publication Date Title
ES527963A0 (es) Un procedimiento de inmunoensayo
BR8300936A (pt) Pinca de ligacao
DK52483D0 (da) Immunoassay
DK320783D0 (da) Klaebemiddel
FI832726A7 (fi) Halogeneringsfoerfarande
ES524460A0 (es) Un metodo de inmunoensayo.
DK606183D0 (da) Stikforbindelse
FI840305A0 (fi) Demolerande produkt
NO834374L (no) Etere
DK513482A (da) Stoedaccelerator
DK453283D0 (da) Forbindelser
ES527737A0 (es) Procedimiento de preparacion de dinucleosidos-monofosfatos
ES525995A0 (es) Procedimiento de obtencion de piridopirimidinonas
ES519779A0 (es) Prensa-recogedora de sarmientos.
ES292964Y (es) Perpiano de construccion
FI832971L (fi) Under vaermepaoverkan krympande foerbindelsemuff
FR2537351B1 (fr) Reglette de raccordement
KR840002462U (ko) 리시이버
ATA286582A (de) Testgeschoss
AT373020B (de) Ruestungstraeger
BR8205287A (pt) Acelerador de percussor
BR8202758A (pt) Amolador de facas
BR8202114A (pt) Cacada de bufalos
AR227230A1 (es) Un corpino mejorado
RO83994A2 (ro) Ciocan de abataj

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970303